- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471691
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)
April 10, 2015 updated by: Hanscom, Thomas, M.D.
Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Huntington Beach, California, United States, 92647
- South Coast Retina
-
Long Beach, California, United States, 90807
- South Coast Retina
-
Santa Monica, California, United States, 90404
- Thomas Hanscom AMC
-
Torrance, California, United States, 90505
- South Coast Retina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age > 18 years
- CRVO or BRVO diagnosis
- For CRVO, clinical evidence of perfused central retinal vein occlusion. A CRVO is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head.
- Central macular edema present on clinical examination and OCT testing with a central point thickness and/or central 1mm subfield thickness > 300 microns after at least 3 months of bevacizumab or steroid therapy.
- Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
- Patients must demonstrate that they are no longer improving on bevacizumab or intravitreal steroid therapy (i.e. no improvement in acuity in 2 consecutive visits)
- BRVO patients treated with grid laser must show residual edema three months following latest laser treatment
- Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria:
- Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
- Participation in another ocular investigation or trial simultaneously
- Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
- Significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
- An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy or severe epiretinal membrane)
- Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
- Evidence of neovascularization of the iris or retina (presence of ischemic CRVO/BRVO)
- Evidence of central atrophy or fibrosis in the study eye
- Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
- History of grid/focal laser or panretinal laser in the study eye in the previous three months
- History of vitreous surgery in the study eye
- History of use of intravitreal, peribulbar, or retrobulbar steroids within three months of the study.
- History of cataract surgery within 6 months of enrollment.
- History of YAG capsulotomy within 2 months of the surgery.
- Visual acuity <20/400 in the fellow eye
- Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.
- History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intravitreal ranibizumab 0.5mg
|
Standard dose
Other Names:
|
Experimental: intravitreal ranibizumab 1.0mg
|
High dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline BCVA
Time Frame: Baseline to month 6
|
Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.
|
Baseline to month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean Change From Baseline in Center Point Thickness
Time Frame: months 1-12
|
months 1-12
|
Change in Mean Best Corrected Visual Acuity From Baseline
Time Frame: months 1-12
|
months 1-12
|
Percentage of Patients With CFT Less Than 300um
Time Frame: Month 6 and 12
|
Month 6 and 12
|
Excess Foveal Thickness
Time Frame: Month 6 and 12
|
Month 6 and 12
|
Total Number of Ranibizumab Injections
Time Frame: month 12
|
month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas O'Hearn, MD, Thomas Hanscom AMC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
February 1, 2014
Study Completion (Actual)
February 1, 2014
Study Registration Dates
First Submitted
November 9, 2011
First Submitted That Met QC Criteria
November 10, 2011
First Posted (Estimate)
November 16, 2011
Study Record Updates
Last Update Posted (Estimate)
April 29, 2015
Last Update Submitted That Met QC Criteria
April 10, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- ML27847
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Fondation Ophtalmologique Adolphe de RothschildBayerActive, not recruiting
-
Shahid Beheshti University of Medical SciencesOphthalmic Research CenterUnknownCentral Retinal Vein OcclusionIran, Islamic Republic of
-
Rudolf Foundation ClinicCompleted
-
Anders KvantaCompletedCentral Retinal Vein OcclusionSweden
-
He Eye HospitalUnknownCentral Retinal Vein OcclusionChina
-
Assaf-Harofeh Medical CenterUnknownCentral Retinal Vein OcclusionIsrael
Clinical Trials on ranibizumab 0.5mg
-
Dongyang People's HospitalRecruiting
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Novartis PharmaceuticalsTerminatedDiabetes | Macular Degeneration | Macular EdemaFrance
-
NovartisCompletedChoroidal NeovascularisationUnited Kingdom
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityCompletedChoroidal NeovascularizationChina
-
Nagoya City UniversityNovartisCompletedNeovascular Age-related Macular DegenerationJapan
-
Novartis PharmaceuticalsCompletedAge-related Macular Degeneration | Choroidal NeovascularizationKorea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
-
Leonard Feiner, MD, PhDNJ Retina (Retina Associates of New Jersey)CompletedAge-related Macular DegenerationUnited States
-
Southern California Desert Retina Consultants, MCCompletedAge-related Macular DegenerationUnited States
-
Kyoto University, Graduate School of MedicineNovartisUnknown